## Supplementary Information

## S1: MODEL DETAILS and Parameters estimations

Table S1 summarizes the values of the parameters we used in the model and the hypotheses we made.

#### Network

For the Erdös-Rényi graph, the only parameter needed is the average number of injecting partners. Wylie *et al.* found that Canadian PWID had a median of 3.5 injecting partners for a period of 30 days ([1](#_ENREF_1)). Sacks-Davis *et al.* reported a median number of 3 injecting partners/PWID, in Melbourne, with a median duration of 3 years for a partnership ([2](#_ENREF_2)). Murray *et al.* estimated the annual number of injecting partners to be 6 in Australia ([3](#_ENREF_3)). Due to the lack of data about network dynamics over the long term, we assumed that PWID had an average of 6 injecting partners for the whole period. We varied this parameter from 3 to 15 in a sensitivity analysis.

#### Population

*Size of the population:* we assumed a population of 10,000 PWID.

*Proportion of current PWID:* we considered a population that consisted exclusively of current PWID, at the beginning of each simulation.

From this point forward, we use the name of the state of the model in Figure 1 to describe the percentage of people in this state.

*Initial distribution in the model:* from ANRS-Coquelicot study for the year 2011 (unpublished).

In details, we estimated the seroprevalence in PWID to be 65.9%. Knowing that viral ARN is present in 65% of seropositive individuals PWID ([4](#_ENREF_4)), we had a viral prevalence of 42.8%. Thus the percentage of uninfected PWID initially is S+S’=57.2%. In our population, 5.4% of individuals were in their first year of injection, and we assumed that they were all susceptible to infection. Since S+S’=57.2%, Thus S=5.4% and S’=51.8%. Due to the short duration of acute hepatitis C (6 months), we assumed that the number of acute hepatitis C cases at a given moment was negligible: A=0%. In ANRS-Coquelicot, 21.4% of infected people, which represent 42.8% of the whole population, were unaware of their infection, thus NDC=9.2%. 33.7% of those who were aware of their infection, i.e. the remaining 33.6% of the whole population, were not linked to care, thus DCNL=11.3%; 47.6% were linked to care, but not treated, so DCL=16.0%; 6.4% were linked and currently undergoing treatment, thus T=2.2%; and 12.3% had a previous unsuccessful or interrupted treatment, so Non-SVR=4.1%.

To avoid that all the initially treated people stop their treatment at the same time and ensure a smooth trajectory at the beginning of the simulations, we drew a past time under treatment for individual in T in a uniform distribution (between 0 and Tt).

*Distribution in the natural history model:* we found no estimation of the distribution of chronically infected PWID according to Metavir Score for the whole infected group for the French PWID population. However, Melin *et al.* provide an estimate at the initiation of treatment, so we assumed that these two distributions were similar ([5](#_ENREF_5)).

We assumed that at the beginning of each simulation, the number of cirrhosis complications was negligible.

We required that in the initial population an individual in a state had a fibrosis score coherent with his state, i.e. no cirrhosis complications in NDC, DCNL, DCL (as we assumed that any individual with complications would always be linked to care), no F2-F3-F4 in DCNL (because we assumed people in these stages would get treated); and no fibrosis score <F2 in T and Non-SVR because in the base case PWID were only treated according to current guidelines - between scores F2 and F4.

*Proportion of men, :* the proportion of men in PWID, 74.5%, was given by ANRS-Coquelicot study.

#### Transitions and care

*Infection rate per infectious contact in S (high risk), , and in S’ (low risk), ’:* We fitted these rates using approximate Bayesian computation (ABC) from some statistics calculated on the ANRS-Coquelicot population. The detailed methods are given in Supplementary Information S2.

*Duration of acute hepatitis, Ta, and probability of spontaneous recovery, pr:* Micallef *et al.* provided an estimated =26% of spontaneous recovery during the =0.5 years of acute hepatitis ([6](#_ENREF_6)).

*Testing rate in chronic hepatitis C, :* We found no direct estimation of the testing rate in the literature. However, the ANRS-Coquelicot study contains data sufficient to derive the rates for active PWID and inactive PWID. From this point forward, we define “active PWID” as the PWID that injected in the past month, and “inactive PWID” as the PWID that did not inject in the past month. We used these two groups as a proxy for current PWID, and former PWID (see Supplementary Information S3). We found a mean duration between infection and diagnosis of =1.25 years for current PWID and =1.45 years for former PWID.

*Linkage to care rate, , and loss to follow up rate, :* we found no data about loss to follow-up for chronically HCV-infected PWID in France. However, the doctoral thesis work of Dr. Bakhao Ndiaye provides this rate among HIV-infected PWID ([7](#_ENREF_7)). We assumed that the rate was similar for both HIV and HCV. Therefore, the annual probability of loss to follow up was 13.8/100 person-year.

The linkage to care rate, , was estimated at 0.39 by ABC (see Supplementary Information S2), corresponding to an average duration of 1/0.39=2.6 years before an individual links to care.

*Treatment:* For incoming DAAs regimens, we used a =90% SVR rate for a 12-week treatment ([8-15](#_ENREF_8)).

In order to take into account the lower effectiveness of treatment in real life compared to the efficacy of the same regimen in clinical trials, we applied a ratio =90.3% to the SVR rate. This ratio corresponds to the ratio of the effectiveness in an observational study to the efficacy in clinical trials of the dual therapy in Melin *et al.* ([5](#_ENREF_5)) (if we consider a SVR rate of 45% for genotype 1 and 80% for genotype 2/3 in clinical trials ([16](#_ENREF_16)) in bitherapy peg-interferon + ribavirin).

*Cessation of drug use rate, :* in the absence of data on a French PWID population, we used Scottish data to get the mean duration between first injection and cessation of drug use: 1/=13.9 years ([17](#_ENREF_17), [18](#_ENREF_18)).

*Non-HCV mortality, :* For mortality of PWID, Lopez *et al.* estimate the annual mortality rate to be 0.0077 per years (y-1 ) for men and 0.0054 y-1 for women among heroin, cocaine and crack cocaine users ([19](#_ENREF_19)).

For former-PWID, we found no data. We hypothesized that mortality among former-PWID was similar to the mortality of adults >20 years in the general population, which was =0.0113 y-1 for men and =0.0098 y-1 for women in 2011 ([20](#_ENREF_20), [21](#_ENREF_21)).

### Natural history parameters

Estimates of the transition rates between stages F0/1, F2/3 and F4 specific to PWID were available in Thein *et al.* ([22](#_ENREF_22)). For complications and HCV-related death rates, we found no estimate for a PWID population, but Salomon *et al.* provided an estimate of HCV-related cirrhosis rates for the general population ([23](#_ENREF_23), [24](#_ENREF_24)). We found no estimate of the HCC rate in decompensated cirrhosis , so we assumed that .

Table S1 Parameters for the model

|  |  |  |  |
| --- | --- | --- | --- |
| **Parameter** | **Value** | **References** | |
| Population size | 10,000\* |  | |
| Initial distribution in the IBM |
| *Susceptible with high risk (S)* | 5.4% |  | ANRS-Coquelicot |
| *Susceptible with low risk (S’)* | 51.8% |
| *Acute hepatitis C (A)* | 0%\* |  | |
| *Non-diagnosed chronic hepatitis C (NDC)* | 9.2% |  | ANRS-Coquelicot |
| *Diagnosed, non-linked to care chronic hepatitis C (DCNL)* | 11.3% |
| *Diagnosed and linked to care chronic hepatitis C (DCL)* | 16.0% |
| *Under treatment (T)* | 2.2% |
| *Non-responders after treatment (Non-SVR)* | 4.1% |
| Initial distribution in the natural history model |
| *F0/F1* | 35% |  | ([5](#_ENREF_5)) |
| *F2/F3* | 51% |
| *F4* | 14% |
| *Decompensated cirrhosis* | 0%\* |  | |
| *HCC* | 0%\* |
|  |  |  | |
| % Men among current PWID () | 75.5% | ANRS-Coquelicot | |
| Number of injecting partners per PWID () | 6\* | See Supplementary Information S1 | |
| Infection rate by injecting partner in S’ (’) | 0.01 y-1partner-1 | See Supplementary Information S2 | |
| Relative risk of infection in S () | 3 |  | ([25](#_ENREF_25)) |
| Duration of high risk period () | 1 y |
| Duration of acute hepatitis C () | 0.5 y |  | ([6](#_ENREF_6)) |
| Probability of spontaneous recovery () | 26% |
| Average time from chronic infection to diagnosis () |  |  | |
| *Current PWID* | 1.25 y | Derived from ANRS-Coquelicot data  (See Supplementary Information S3) | |
| *Former PWID* | 1.45 y |
| Average time before linkage to care () | 2.6 y | See Supplementary Information S2 | |
| Loss to follow-up rate () | 14%/y | ([7](#_ENREF_7)) | |
| Treatment: incoming DAAs regimens |  |  | |
| *Duration* () | 12 weeks |  | ([8-10](#_ENREF_8), [12-14](#_ENREF_12), [26-28](#_ENREF_26)) |
| *SVR rate* () *– treatment naive - all genotypes- clinical trials* | 90% |
| Ratio of the effectiveness in real life to the efficacy in clinical trials () | 0.903 | ([5](#_ENREF_5)) | |
| Mortality () |  |  | |
| *Current PWID - men* | 0.0077 y-1 |  | ([19](#_ENREF_19)) |
| *Current PWID - women* | 0.0054 y-1 |
| *Former PWID - men* | 0.0114 y-1 |  | ([20](#_ENREF_20), [21](#_ENREF_21)) |
| *Former PWID - women* | 0.0098 y-1 |
| Duration of injecting career () | 13.9 y | ([17](#_ENREF_17), [18](#_ENREF_18)) | |
| Transition rate F0/F1→ F2/F3 () | 0.052 y-1 |  | ([22](#_ENREF_22)) |
| Transition rate F2/F3→ F4 () | 0.054 y-1 |
| Transition rate F4→Decompensated cirrhosis () | 0.04 y-1 |  | ([23](#_ENREF_23), [24](#_ENREF_24)) |
| Transition rate F4→HCC () | 0.021 y-1 |
| Transition rate Decompensated cirrhosis→Death related to HCV () | 0.306 y-1 |
| Transition rate HCC→Death related to HCV () | 0.433 y-1 |
| Transition rate Decompensated cirrhosis→HCC () | 0.021 y-1 |

\* Hypothesis

IBM: Individual-based model

SVR: Sustained virological response

PWID: People who inject drugs

y-1 : per year

HCC: Hepatocellular carcinoma

DAA: Direct-acting antiviral

HCV: Hepatitis C virus

## S2: Estimating the infection rate and the linkage to care rate by Approximate Bayesian Computation (ABC)

For sophisticated models where likelihood can be numerically intractable, methods based on likelihood fail to provide good estimates for parameters. Approximate Bayesian Computation (ABC) is a computational method used to infer some parameters without likelihood estimation ([29](#_ENREF_29)).

We denote by the set of parameters to deriveand the set of observed data.

### Reminder: Bayesian inference

To clearly understand the motivation of ABC, we begin with a quick reminder about the main principle of Bayesian inference. The main idea of the Bayesian inference is to consider as a random variable with a probability distribution.

Let be the *prior distribution* of the parameters. The prior distribution is chosen to reflect the uncertainty around *before* any data is observed. Ideally, the variable must be the most informative possible (for example, a choice for the parameter of an Erdős–Rényi model can be a beta distribution).

Let be the likelihood of given the data in the model. This likelihood corresponds to the information given by the data.

The *posterior distribution* of the parameters is defined as the distribution of taking into account the available data, i.e. . According to Bayes theorem, it is given by:

Where means that the two quantities are proportional. The posterior distribution is more informative than the prior distribution and we expect a tighter distribution. Bayesian inference aims at estimating this distribution and its mean or median can be chosen as estimates of the parameter .

### Main idea of ABC

The key point of Bayesian inference is the computation of the likelihood . However, for a complex model, this may be intractable. The main idea of ABC is to 1) catch information from the observed data by replacing the posterior distribution by the target distribution (called the *partial posterior distribution*), where is a vector of summary statistics of the data (for example, the number of edges or the number of triangles of the graph); and 2) use the generative model to avoid any likelihood-like computation.

Let be the value of in the data. ABC aims to approximate by considering simulations for which is closed to .

The basic form of the ABC is thus based on a rejection algorithm, and implemented as follows:

1. Generate N random draws in the joint law of The parameter is generated from the prior distribution π, and the vector of summary statistics si is calculated for the ith data set that is simulated from the model with parameter .
2. Associate to the ith simulation, the weight , where is a tolerance threshold and a (possibly multivariate) smoothing kernel.
3. The distribution in which denotes the Dirac mass at , approximates the target distribution.

In our study, we used an improved version of this rejection algorithm, based on linear adjustments of the parameters: we assumed a linear link between and for observations under the tolerance threshold, i.e. can be approximated by a function of the form , and is replaced by:

,

The slope is estimated by regressions of on with simulations, using the package “abc” ([30](#_ENREF_30)) of the statistical software R ([31](#_ENREF_31)).

### Application of ABC

We have two parameters of interest: the injection rate per infectious edge in the network for an experienced PWID, and the rate of linkage to care. We have also nuisance parameters (i.e. parameters necessary for the model): the distribution in DCL, DCNL, T, and Non-SVR in 2004. These parameters are estimated from the following data of ANRS Coquelicot study:

* Prevalence among active PWID in 2011: 42.8%
* Distribution of inactive PWID in DCNL: 11.3%
* Distribution of inactive PWID in NDC: 16%
* Distribution of inactive PWID in T: 2.2%.

Since the Coquelicot study allowed us to have the prevalence in the model in 2004, we performed simulations over the 2004-2011 period. We used specific data available for this period about the mortality among former PWID, the testing rate, and the distribution in S, S’, and NDC instead of the parameters we used in the base case (see Table S2).

Concerning the parameters of ABC, we performed 25,000 simulations, the tolerance threshold was 0.1 and we used an Epanechnikov kernel, i.e. for all in ℝ:

To ensure positivity of and , these parameters were log-transformed and the distribution in 2004 of infected and diagnosed individuals was logit-transformed to ensure it corresponded to a distribution and summed to 100%. The prior law distributions were:; where is a uniform law on . The prior law distributions of DCL, DCNL, T ,and Non-SVR were uniform distributions (renormalized so that the distribution in the model summed to 100% with respective means of 14%, 8.8%, 2.1%. and 4.5% for the afore-mentioned states).

Table S2 - parameters for ABC implementation

|  |  |  |  |
| --- | --- | --- | --- |
| **Parameter** | **Value** | **References** | |
| Distribution in 2004 in the IBM | | |
| *S* | 3% | ANRS-Coquelicot | |
| *S’* | 43% |
| *NDC* | 16.7% |
| % Men (current PWID) | 80.7% |
| Duration of treatment (bitherapy) | 36 weeks | ([16](#_ENREF_16)) | |
| %SVR bitherapy (naïve, all genotypes) | 58% | ([5](#_ENREF_5)) | |
| Former PWID mortality (Men -Women) | 11.3 - 9.6/1000 PY | ([20](#_ENREF_20), [21](#_ENREF_21)) | |

IBM: Individual-based model

PWID: People who inject drugs

SVR: sustained virological response

PY: person-year

### Results

We found the following results (with 95% confidence intervals), depending on the average number of injecting partners:

**Table S3** Infection rate per partner and time to linkage to care estimates by Approximate Bayesian Computation, according to the average number of injecting partners (with 95% confidence intervals)

|  |  |  |
| --- | --- | --- |
| Average number of injecting partners | Infection rate per partner (y-1) | Time to linkage to care (y) |
| 3 | 0.019 (0.004-0.045) | 2.6 (2.3-2.9) |
| 6 | 0.01 (0.003-0.02) | 2.6 (2.3-2.9) |
| 15 | 0.004 (0.002-0.008) | 2.6 (2.3-2.9) |

## S3: estimating the time before diagnosiS by maximum likelihood FROM the data of the ANRS COQUELICOT STUDY

We wanted to estimate the test rate using the data available in the Coquelicot study. PWID undergo test until they are diagnosed with HCV. We assume that to each PWID without HCV diagnosis is associated a Poisson process of rate , that is to say that intervals between successive tests follow exponential distribution with parameter .

Let’s assume that we observed PWID without HCV diagnosis, i.e. people non-infected or unaware of their infection.

For each PWID , we observed :

• the delay between the beginning of his/her injecting career (i.e. the first injection) and the time of the Coquelicot study

• indicator of the presence of a HCV test before the survey

• the time of the last test done before the survey

We denote by the observations of for the PWID, and the number of PWID in the survey with a previous HCV test.

We define the likelihood of conditionnally to the as

With be the number of tests done on the interval for the individual , and the density of knowing that and and

Proposition: The maximum-likelihood estimator of is

Proof: follows a Poisson distribution of parameter .

We have:

1. Knowing and , the survival function of is,

With the elapsed time between the first injection and the kth test of the PWID. Knowing that he/she had had tests, , the tests repartition on follows a uniform distribution on the injecting period, as the PWID are tested following a Poisson process. Thus, if for , follows an uniform distribution on we have :

Moreover,

Thus,

Then,

Therefore,

And the likelihood for a sampling:

Therefore,

Where is a constant. It follows that the maximum-likelihood estimator of be that proposed above.

### Results

Using the data of the ANRS Coquelicot survey, we found an estimate of 0.80 years-1 for active PWID and 0.69 years-1 for inactive PWID (PWID after cessation of drug use), corresponding to an average duration of 1.25 and 1.45 years before diagnosis.

## S4: Evolution of the prevalence, incidence, and the number of cirrhosis complications OVER the first 40 years

|  |
| --- |
| A. |
| B. C:\Thèse\simulations_10000\pour_evolution_outputs\scenarios\evolution incidence.png |

|  |
| --- |
| C. C:\Thèse\simulations_10000\pour_evolution_outputs\scenarios\evolution complications.png |

**Figure S1** evolution of A) the prevalence of HCV in the population, B) the incidence of HCV infection and C) the number of new cirrhosis complications over the first 40 years.

## S5: Sensitivity analysEs

We present the results of some sensitivity analyses. First, the parameters’ values used in the deterministic sensitivity analysis are summarized in Table S3. The results are represented in a tornado diagram (Figure S2), giving the most sensitive parameters according to each outcome. Briefly, the prevalence at 10 years is mainly sensitive to the infection rate per partner and the parameters determining the access to treatment (transition rate from F0/F1 to F2/F3, linkage to care and loss to follow-up rates). The incidence at 10 years is mainly impacted by parameters related to the infection risk: infection rate, average time before cessation of drug use, relative risk of infection during the first year. The cumulative number of cirrhosis complication over 10 years is mainly impacted by the transition rate to cirrhosis, the initial fibrosis distribution and the linkage to care and loss to follow-up rates; meanwhile over 40 years, the average time to diagnosis has also an impact on it.

Table S4 gives the results for settings with an average of 3, 6 (base case), and 15 injecting partners. The results show similar incidence and prevalence at 10 years, and number of new complications in the population at 40 years.

Figures S3 and S4 presents the results when we increased to 5 and 10 times the base case. Base case analysis results also presented for comparison. These three settings correspond respectively to a stable, increasing and decreasing prevalence at 10 years in the reference scenario. The conclusion of the base case remains valid in these other two settings. The clinical benefits are even better in setting with higher infection rates.

Table S3 Description of the sensitivity analysis

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Parameters** | **Base case value** | **Sensitivity analysis** | **References** | |
| Initial distribution in the natural history model |
| *F0/F1* | 35% | 50% |  | Assumption |
| *F2/F3* | 51% | 40% |
| *F4* | 14% | 10% |
|  |  |  |  | |
| Number of injecting partners/PWID () | 6 | 3 – 15 | Assumption | |
| Infection rate in S’ per infected injecting partner (’) | 0.01 y-1partner-1 | 0.003 – 0.02 | See Supplementary Information S2 | |
| Relative risk of infection in S () | 3 | 1 – 10 | Assumption | |
| Relative risk of reinfection after SVR per infected partner | 1 | 1-10 | Assumption | |
| Time between chronic infection and diagnosis (current PWID/former PWID) () | 1.25/1.45 years | 0.5 – 7.8 | Scenario 2 -Value in UK ([32](#_ENREF_32)) | |
| Average time before linkage to care ()/ Loss to follow-up rate () | 2.6 y  / 14%/year | 0.5 - 4  / 5 – 20 | Scenario 3 – Assumption | |
| Current PWID mortality (Men/Women) () | 0.0077 y-1/  / 0.0054 y-1 | 0.0058 - 0.0097  / 0.0041 - 0.0068 | Assumption | |
| Former PWID mortality (Men/Women) () | 0.0114 y-1  / 0.0098 y-1 | 0.0086 - 0.0143  / 0.0074 - 0.0123 | Assumption | |
| Average duration of injecting career () | 13.9 years | 9.5 – 17 | ([17](#_ENREF_17), [18](#_ENREF_18)) | |
| Transition rate F0/F1→ F2/F3 () | 0.052 y-1 | 0.031 - 0.074 |  | ([22](#_ENREF_22)) |
| Transition rate F2/F3→ F4 () | 0.054 y-1 | 0.025 – 0.101 |
| Transition rate F4→Decompensated cirrhosis () | 0.04 y-1 | 0.032 – 0.052 |  | ([23](#_ENREF_23), [24](#_ENREF_24)) |
| Transition rate F4→HCC () | 0.021 y-1 | 0.017 – 0.028 |
| Transition rate Decompensated cirrhosis→Death related to HCV () | 0.306 y-1 | 0.129 – 0.395 |
| Transition rate HCC→Death related to HCV () | 0.433 y-1 | 0.319 – 0.499 |
| Transition rate Decompensated cirrhosis→HCC () | 0.021 y-1 | 0.017 – 0.028 |

PWID: People who inject drugs

y-1 : per year

HCC: Hepatocellular carcinoma

HCV: Hepatitis C virus

SVR: Sustained Virological Response



Figure S2 Tornado diagrams for the sensitivity analysis of A. prevalence at 10 years; B. incidence at 10 years; C. cirrhosis complications avoided over 10 years; D. change in the number of cirrhosis complications occurring over 40 years. The diagrams represent the change in the outcomes for each parameter varied. Parameters are sorted according to the magnitude of variation of the outcome. Only the 10 most sensitive parameters were plotted. The values on the graph indicate the parameters’ values used.

Table S4 Results per scenario for an average number of 3, 6 and 15 injecting partners.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Scenario | Average number of injecting partners | Prevalence at 10 years (%) | Incidence at 10 years  (/100 PY) | % cirrhosis complications avoided compared to Scenario 1 over 10 years | % cirrhosis complications avoided compared to Scenario 1 over 40 years |
|  |  | mean (95% CI) | mean (95% CI) | mean (95% CI) | mean (95% CI) |
| **Scenario 1** | 3 | **24.6 (24.5;24.7)** | **0.77 (0.74;0.79)** | **/** | **/** |
| 6 | **24.9 (24.8;24.9)** | **0.84 (0.81;0.87)** | **/** | **/** |
| 15 | **24.9 (24.9;25)** | **0.85 (0.82;0.88)** | **/** | **/** |
| Scenario 2 | 3 | 24.4 (24.3;24.5) | 0.75 (0.73;0.78) | -1.2 (-2.6;0.3) | -0.9 (-2.7;0.9) |
| 6 | 24.7 (24.6;24.8) | 0.83 (0.8;0.86) | -1.2 (-2.6;0.2) | -0.8 (-2.6;0.9) |
| 15 | 24.8 (24.7;24.8) | 0.86 (0.83;0.89) | -1.2 (-2.6;0.1) | -1.7 (-3.4;0.1) |
| Scenario 3 | 3 | 23.4 (23.4;23.5) | 0.72 (0.69;0.74) | -9.6 (-10.9;-8.2) | -11.5 (-13.1;-10) |
| 6 | 23.7 (23.6;23.8) | 0.8 (0.77;0.83) | -9.8 (-11.1;-8.5) | -11.5 (-13.1;-10) |
| 15 | 23.8 (23.7;23.8) | 0.81 (0.79;0.84) | -9.6 (-10.9;-8.3) | -11.9 (-13.4;-10.3) |
| Scenario 4 | 3 | 23.3 (23.2;23.4) | 0.72 (0.69;0.74) | -11.7 (-13;-10.4) | -13.1 (-14.6;-11.6) |
| 6 | 23.6 (23.5;23.7) | 0.78 (0.76;0.81) | -11.6 (-12.9;-10.3) | -13.1 (-14.6;-11.6) |
| 15 | 23.7 (23.6;23.7) | 0.81 (0.78;0.84) | -11.6 (-12.9;-10.4) | -13.2 (-14.7;-11.6) |
| Scenario 5 | 3 | 22.7 (22.6;22.7) | 0.71 (0.69;0.74) | -2.9 (-4.2;-1.5) | -12.2 (-13.8;-10.7) |
| 6 | 22.9 (22.9;23) | 0.78 (0.75;0.81) | -3.2 (-4.6;-1.8) | -11.7 (-13.3;-10) |
| 15 | 23 (22.9;23.1) | 0.79 (0.77;0.82) | -3.1 (-4.4;-1.7) | -12.4 (-14;-10.9) |
| Scenario 6 | 3 | 11.5 (11.5;11.6) | 0.36 (0.34;0.38) | -0.2 (-1.6;1.3) | -7.5 (-9;-5.9) |
| 6 | 11.6 (11.6;11.7) | 0.39 (0.37;0.41) | -0.6 (-2;0.9) | -7 (-8.6;-5.4) |
| 15 | 11.6 (11.6;11.7) | 0.4 (0.38;0.42) | -0.5 (-1.9;1) | -7.4 (-9;-5.8) |
| Scenario 7 | 3 | 7 (7;7.1) | 0.21 (0.2;0.23) | -15.1 (-16.4;-13.7) | -29 (-30.1;-27.8) |
| 6 | 7 (7;7.1) | 0. 23 (0.22;0.25) | -15.3 (-16.6;-14) | -29 (-30.1;-27.9) |
| 15 | 7 (7;7.1) | 0. 23 (0.22;0.25) | -15.3 (-16.6;-14.1) | -29.6 (-30.7;-28.4) |

CI: Confidence interval

PY: person-year

|  |  |  |
| --- | --- | --- |
|  | Prevalence at 10 years | Incidence at 10 years |
| Base case |  | C:\Thèse\simulations_10000\resultats\scenarios\boxplots_incidences10ans1.png |
| Infection rate x 5 |  | C:\Thèse\simulations_10000\resultats\betax5x10\boxplots_incidences10ans1.png |
| Infection rate x 10 |  | C:\Thèse\simulations_10000\resultats\betax5x10\boxplots_incidences10ans1.png |

Figure S3 Boxplots of the prevalence and incidence at 10 years according to the scenario in three settings: base case rate, infection rate/infected partners x 5 and infection rate/infected partners x 10

|  |  |  |
| --- | --- | --- |
|  | % cirrhosis complications avoided compared to Scenario 1 over 10 years | % cirrhosis complications avoided compared to Scenario 1 over 40 years |
| Base case |  |  |
| Infection rate x 5 |  |  |
| Infection rate x 10 |  |  |

Figure S4 Average percentage of cirrhosis complications avoided over 10 and 40 years according to the scenario in three settings: base case, infection rate/infected partners x 5 and infection rate/infected partners x 10

# REFERENCES

1. Wylie JL, Shah L, Jolly AM. Demographic, risk behaviour and personal network variables associated with prevalent hepatitis C, hepatitis B, and HIV infection in injection drug users in Winnipeg, Canada. BMC Public Health 2006;6:229.

2. Sacks-Davis R, Daraganova G, Aitken C, Higgs P, Tracy L, Bowden S, Jenkinson R, et al. Hepatitis C virus phylogenetic clustering is associated with the social-injecting network in a cohort of people who inject drugs. PLoS One 2012;7:e47335.

3. Murray JM, Law MG, Gao Z, Kaldor JM. The impact of behavioural changes on the prevalence of human immunodeficiency virus and hepatitis C among injecting drug users. Int J Epidemiol 2003;32:708-714.

4. Meffre C, Le Strat Y, Delarocque-Astagneau E, Dubois F, Antona D, Lemasson JM, Warszawski J, et al. Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors. J Med Virol 2010;82:546-555.

5. Melin P, Chousterman M, Fontanges T, Ouzan D, Rotily M, Lang JP, Marcellin P, et al. Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study. Eur J Gastroenterol Hepatol 2010;22:1050-1057.

6. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006;13:34-41.

7. Ndiaye B. Facteurs de risque de l'accès tardif aux soins et de la perte de vue chez les patients infectés par le VIH suivis à Bruxelles et dans la région Nord Pas-de-Calais: Université de Lille 2; 2009.

8. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon S, Schultz M, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-1887.

9. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-1493.

10. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889-1898.

11. Hezode C, Hirschfield GM, Ghesquiere W, Sievert W, Rodriguez-Torres M, Shafran SD, Thuluvath PJ, et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut 2014.

12. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879-1888.

13. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, Shiffman ML, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014;370:1973-1982.

14. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Lawitz E, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370:211-221.

15. Sulkowski MS, Jacobson IM, Nelson DR. Daclatasvir plus sofosbuvir for HCV infection. N Engl J Med 2014;370:1560-1561.

16. NICE. PegInterferon alfa and ribavirin for the treatment of mild chronic hepatitis C; 2006.

17. Fazito E, Cuchi P, Mahy M, Brown T. Analysis of duration of risk behaviour for key populations: a literature review. Sex Transm Infect 2012;88 Suppl 2:i24-32.

18. Copeland L, Budd J, Robertson JR, Elton RA. Changing patterns in causes of death in a cohort of injecting drug users, 1980-2001. Arch Intern Med 2004;164:1214-1220.

19. Lopez D, Martineau H, Palle C. Mortalité liée aux drogues illicites: OFDT, 2004.

20. INSEE. Taux de mortalité par sexe et groupe d'âges. In; 2012.

21. INSEE. Population par sexe et groupes d'âges quinquennaux. 2013.

22. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008;48:418-431.

23. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003;290:228-237.

24. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Empirically calibrated model of hepatitis C virus infection in the United States. Am J Epidemiol 2002;156:761-773.

25. Sutton AJ, Gay NJ, Edmunds WJ, Hope VD, Gill ON, Hickman M. Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales. BMC Infect Dis 2006;6:93.

26. Bourliere M, Khaloun A, Wartelle-Bladou C, Oules V, Portal I, Benali S, Adhoute X, et al. Chronic hepatitis C: Treatments of the future. Clin Res Hepatol Gastroenterol 2011;35 Suppl 2:S84-95.

27. Pawlotsky JM. New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges. Gastroenterology 2014;146:1176-1192.

28. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourliere M, Sulkowski MS, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1604-1614.

29. Marin J-M, Pudlo P, Robert CP, Ryder RJ. Approximate Bayesian computational methods. Statistics and Computing 2012;22:1167-1180.

30. Csilléry K, François O, Blum MG. abc: an R package for approximate Bayesian computation (ABC). Methods in ecology and evolution 2012;3:475-479.

31. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. In; 2014.

32. Martin NK, Hickman M, Miners A, Hutchinson SJ, Taylor A, Vickerman P. Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons. BMJ Open 2013;3.